期刊文献+

MAPK在病理性瘢痕和瘢痕癌中的表达

The Correlation Research about MAPK with the Pathological Scar and Scar Cancer
下载PDF
导出
摘要 目的探讨MAPK及其mRNA与病理性瘢痕上皮和瘢痕癌的相关性。方法采用免疫组织化学(SP)法和核酸分子原位杂交技术分别检测正常皮肤表皮,病理性瘢痕上皮和瘢痕癌三组组织中MAPK蛋白和mRNA的表达;结合图像分析,分别计算三组组织中所检指标的平均光密度和阳性面积,所有数据运用SPSS16.0软件包进行统计学分析。结果 MAPK蛋白和mRNA在正常皮肤表皮、病理性瘢痕上皮和瘢痕癌组织中分别呈阴性表达、弱阳性表达和强阳性表达。瘢痕癌组表达水平(阳性面积)、表达强度(平均光密度)与正常皮肤、病理性瘢痕组比较,差异均有统计学意义(P均<0.01);但正常皮肤组与病理性瘢痕组比较,差异无统计学意义(P>0.05)。且在瘢痕癌组织中,MAPK及其mRNA的表达呈正相关。结论 MAPK及其mRNA在瘢痕癌中的高表达,与瘢痕癌的发生有相关性,可作为瘢痕癌靶向治疗的靶点,但在病理性瘢痕上皮中的表达不具有特殊意义。 Objective Explore the correlation about the MAPK and MAPK mRNA with the pathological scar cancer and scar carcinoma. Methods The MAPK protein and MAPK mRNA were detected in normal skin epidermis, pathological scar epithelium and scar cancer three groups tissues by the immunohistochemical method of S-P and in situ hybridization. The analysis of image were combinted, and calculated the optical density and positive area indicators seized in the inspection organization, and all data was input into the computer and statistically analyzed with SPSS16.0 software. Results MAPK and its mRNA showed negative expression in nor- mal skin epidermis, showed weakly positive expression in pathological scar epithelium, showed strongly posi- tive expression in scar carcinoma tissue. The expression of levels (positive area) and intensity (mean optical densit) differences were statistically significant ( P 〈 0.01 ) by compared with normal skin group and skin scar group. But the differences of expression has no statistically significant between normal skin group and pathological scar group. Correlated analysis showed: it was positive correlation between the expression levels of MAPK and its mRNA. Conclusion The MAPK protein and its mRNA showed strong positive expression in the scar cancer tissue, which may be play important roles in the occurrence of scar carcinoma, can be used as scar cancer targeted therapy target. The expression of MAPK protein and its mRNA in pathological scar epithelium does not have a special meaning.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2013年第7期647-650,共4页 The Chinese Journal of Dermatovenereology
基金 贵州省攻关项目(2010-3080) 遵义医学院自然科学类招标课题(F-552)
关键词 皮肤病理性瘢痕 瘢痕癌 MAPK 癌变 治疗靶点 Skin pathological scar Scar cancer MAPK Carcinogenesis Therapeutic targets
  • 相关文献

参考文献9

  • 1McCubreyJA, Steelman LS, Chappell WH, et al. Roles of the Raf/ MEKIERK pathway in cell growth, malignant transformation and drug resistance[J] . Biochim Biophys Acta ,2007 ,1773 (8) : 1263 - 1284.
  • 2Wong KK. Recent developments in anti-cancer agents targeting the Ras/ Raf/MEKIERK pathway[J]. Recent Pat Anticancer Drug Discov, 2009 ,4( 1) :28 -35.
  • 3王海青,郭瑞珍.RAS-RAF-MEKl/2/-ERKl/2 MAPK信号转导通路及其与皮肤肿瘤的关系[J].中国皮肤性病学杂志,2013,27(2):201-203. 被引量:5
  • 4崔巍,王硕仁,朱陵群,等.平均光密度值分析法和阳性染色面积分析法在免疫组化图像分析中的对比研究[A].2008中华中医药学会内科分会中医内科学科建设研讨会论文汇编,2008:148-151.
  • 5Lee SH, Shin MS, Kim HS, et al. Somatic mutations of Fas (Apo-ll CD95 ) gene in cutaneous squamous cell carcinoma arising from a bum scar] J J. TheJournal of Investigative Dermatology ,2000 ,114 ( I ) : 122 -126.
  • 6ObaJ ,Nakahara T ,Abe T ,et al. Expression of c-Kit,p-ERK and cyclin 01 in malignant melanoma: an immunohistochemical study and analysis of prognostic value[J].J Dermatol Sci ,2011 ,62( 2) : 116 -123.
  • 7Ebisuya M, Kondoh K, Nishida E. The duration, magnitude and compart?mentalization of ERK MAP kinase activity: mechanisms for providing signaling specificity[J] .J Cell Sci, 2005 ,118 (14 ) : 2997 - 3002.
  • 8Huang 0, Ding Y ,Luo WM, et al. Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vi?vo[J]. Cancer Res,2008,68(1) :81-88.
  • 9XieJ ,Li Y, Huang Y, et al. Anesthetic pentobarbital inhibits prolifera?tion and migration of malignant glioma cells[J] . Cancer Lett, 2009 ,282 (1) :35 -42.

二级参考文献28

  • 1Raman M,Chen W,Cobb MH. Differential regulation and properties of MAPKs[J].Oncogene,2007,(22):3100-3112.doi:10.1038/sj.onc.1210392.
  • 2McCubrey JA,Steelman LS,Chappell WH. Roles of the Raf/MEK/ERKpathway in cell growth,malignant transformation and drug resistance[J].Biochimica Et Biophysica Acta,2007,(08):1263-1284.
  • 3Sato S,Fujita N,Tsuruo T. Involvement of 3-phosphoinositide-dependent protein kinase-1 in the MEK/MAPK signal transduction pathway[J].Journal of Biological Chemistry,2004,(32):33759-33767.
  • 4H agemann C,Blank JL. The ups and downs of MEK kinase in-teractions[J].Cellular Signalling,2001,(12):863-875.
  • 5Vakiani E,Solit DB. KRAS and BRAF:drug targets and predictive biomarkers[J].Journal of Pathology,2011,(02):219-229.
  • 6Bos JL,Rehmann H,Wittinghofer A. GEFs and GAPs:critical element in the controlof small G proteins[J].Cell,2007,(05):865-877.doi:10.1016/j.cell.2007.05.018.
  • 7Wong KK. Recent developments in anticancer agents targeting the Ras/Raf/ MEK/ERK pathway[J].Recent Pat Anticancer Drug Discov,2009,(01):28-35.
  • 8Tamamori-Adachi M,Ito H,Sumrejkanchanakij P. Critical role of cyclin D1nuclear import in cardiomyocyte proliferation[J].Circulation Research,2003,(01):12-19.
  • 9Pons M,Quintanilla M. Molecular biology of malignant melanoma and other cutaneous tumors[J].Clin Transl oncol,2006,(07):466-474.
  • 10Uribe P,Gonzalez S. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin:molecular bases for EGFR-targeted therapy[J].Patnol Res Prast,2011,(06):337-342.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部